Prevalência da infecção anogenital pelo papilomavírus humano (HPV) em usuários de terapia imunobiológica
Ano de defesa: | 2021 |
---|---|
Autor(a) principal: | |
Orientador(a): | |
Banca de defesa: | , |
Tipo de documento: | Dissertação |
Tipo de acesso: | Acesso aberto |
Idioma: | por |
Instituição de defesa: |
Universidade do Oeste Paulista
|
Programa de Pós-Graduação: |
Mestrado em Ciências da Saúde
|
Departamento: |
Mestrado em Ciências da Saúde
|
País: |
Brasil
|
Palavras-chave em Português: | |
Palavras-chave em Inglês: | |
Área do conhecimento CNPq: | |
Link de acesso: | http://bdtd.unoeste.br:8080/jspui/handle/jspui/1329 |
Resumo: | Introduction: Patients using immunobiological drugs are at increased risk of presenting or reactivating latent or occult infections and unnoticed neoplasms. Screening prior to the use of these drugs includes warding off infections, including tuberculosis, viral hepatitis B and C, syphilis, human immunodeficiency virus (HIV), and opportunistic pathogens in immunosuppressed patients. However, human papillomavirus (HPV), a highly prevalent agent in our country and precursor of benign or even carcinogenic warts, is not routinely screened. Information on HPV infection in immunobiological users is scarce or conflicting, and there are no studies evaluating the prevalence of HPV in the anogenital region among users of different classes of these medications for the treatment of different immunomediated chronic inflammatory diseases, when compared to that of non-users of this medication. Objective: To compare the prevalence of anogenital HPV infection in immunobiological users for the treatment of immunomediated chronic inflammatory diseases with that of non-users of this medication. Materials and methods: HPV positivity in 114 immunobiological users (infliximab, etanercept, adalimumab, secuquinumab and ustequinumab) were evaluated clinically and by polymerase chain reaction (PCR) for the treatment of immunomediated chronic inflammatory diseases (psoriasis, psoriatic arthritis, suputive hydrosadenitis, rheumatoid arthritis, ankylosing spondylitis and Chron's disease) and 114 individuals not using this therapy or other immunosuppressants, with dermatoses, except psoriasis, and not carriers of conditions predisposing to HPV infection (diabetes mellitus, hematological diseases, HIV infection, hepatitis B or C, neoplasms and organ transplants). Results: The prevalence of low-risk HPV in the immunobiological users and non-users groups was 16.3% and 10.3%, respectively (p= 0.524). The low-risk types found were 6, 11, 40, 42 and 44. The prevalence of high-risk HPV was 20.2% in users versus 18.4% in non-users (p= 0.737), distributed according to the following types: 16 (6.8%); 18 (11.4%); not 16/18 (81.8%). After pairing by gender and age, the prevalence of high-risk HPV was 21.0% and 12.9% for immunobiological users and non-users, respectively (p= 0.231). Separating by class of immunobiologicals, the prevalence of high-risk HPV among users of anti-TNF-α was 20.0% and anti-IL 21.6%, with no significant association (p= 0.482). Thus, there was no association between both groups and the prevalence of low-risk or high-risk HPV. Conclusion: The prevalence of anogenital HPV infection in patients with chronic immune-mediated inflammatory diseases treated with immunobiologicals is similar to that of patients not using these drugs. |
id |
UOES_b04190abb9e21fd1563bc78f505431ad |
---|---|
oai_identifier_str |
oai:bdtd.unoeste.br:jspui/1329 |
network_acronym_str |
UOES |
network_name_str |
Biblioteca Digital de Teses e Dissertações da UNOESTE |
repository_id_str |
|
spelling |
Abreu, Marilda Aparecida Milanez Morgado dehttp://lattes.cnpq.br/7386113426973769Nai, Gisele Alborghettihttps://orcid.org/0000-0003-1674-7371http://lattes.cnpq.br/6057606215850166Duarte, Artur Antoniohttp://lattes.cnpq.br/6738651856959288http://lattes.cnpq.br/8687483769115762RONCADA, Eduardo Vinicius Mendes2021-04-12T18:17:26Z2021-02-23RONCADA , Eduardo Vinicius Mendes. Prevalência da infecção anogenital pelo papilomavírus humano (HPV) em usuários de terapia imunobiológica. 2021. Dissertação (Mestrado em Ciências da Saúde) - Universidade do Oeste Paulista, Presidente Prudente, SP, 2021 .http://bdtd.unoeste.br:8080/jspui/handle/jspui/1329Introduction: Patients using immunobiological drugs are at increased risk of presenting or reactivating latent or occult infections and unnoticed neoplasms. Screening prior to the use of these drugs includes warding off infections, including tuberculosis, viral hepatitis B and C, syphilis, human immunodeficiency virus (HIV), and opportunistic pathogens in immunosuppressed patients. However, human papillomavirus (HPV), a highly prevalent agent in our country and precursor of benign or even carcinogenic warts, is not routinely screened. Information on HPV infection in immunobiological users is scarce or conflicting, and there are no studies evaluating the prevalence of HPV in the anogenital region among users of different classes of these medications for the treatment of different immunomediated chronic inflammatory diseases, when compared to that of non-users of this medication. Objective: To compare the prevalence of anogenital HPV infection in immunobiological users for the treatment of immunomediated chronic inflammatory diseases with that of non-users of this medication. Materials and methods: HPV positivity in 114 immunobiological users (infliximab, etanercept, adalimumab, secuquinumab and ustequinumab) were evaluated clinically and by polymerase chain reaction (PCR) for the treatment of immunomediated chronic inflammatory diseases (psoriasis, psoriatic arthritis, suputive hydrosadenitis, rheumatoid arthritis, ankylosing spondylitis and Chron's disease) and 114 individuals not using this therapy or other immunosuppressants, with dermatoses, except psoriasis, and not carriers of conditions predisposing to HPV infection (diabetes mellitus, hematological diseases, HIV infection, hepatitis B or C, neoplasms and organ transplants). Results: The prevalence of low-risk HPV in the immunobiological users and non-users groups was 16.3% and 10.3%, respectively (p= 0.524). The low-risk types found were 6, 11, 40, 42 and 44. The prevalence of high-risk HPV was 20.2% in users versus 18.4% in non-users (p= 0.737), distributed according to the following types: 16 (6.8%); 18 (11.4%); not 16/18 (81.8%). After pairing by gender and age, the prevalence of high-risk HPV was 21.0% and 12.9% for immunobiological users and non-users, respectively (p= 0.231). Separating by class of immunobiologicals, the prevalence of high-risk HPV among users of anti-TNF-α was 20.0% and anti-IL 21.6%, with no significant association (p= 0.482). Thus, there was no association between both groups and the prevalence of low-risk or high-risk HPV. Conclusion: The prevalence of anogenital HPV infection in patients with chronic immune-mediated inflammatory diseases treated with immunobiologicals is similar to that of patients not using these drugs.Introdução: Pacientes usuários de medicamentos imunobiológicos têm risco aumentado de apresentar ou reativar infecções latentes ou ocultas e neoplasias desapercebidas. O screening prévio ao uso destes medicamentos inclui afastar infecções, incluindo tuberculose, hepatites virais B e C, sífilis, vírus da imunodeficiência humana (HIV) e patógenos oportunistas em imunodeprimidos. Entretanto, o papilomavirus humano (HPV), um agente altamente prevalente no nosso meio e precursor de verrugas benignas ou mesmo cancerígenas, não é rotineiramente rastreado. As informações quanto à infecção pelo HPV nos pacientes usuários de imunobiológicos são escassas ou conflitantes, não havendo estudos que avaliem a prevalência de HPV na região anogenital, entre usuários de classes distintas destas medicações, para o tratamento de diferentes doenças inflamatórias crônicas imunomediadadas, quando comparada com a de não usuários desta medicação. Objetivo: Comparar a prevalência da infecção anogenital pelo HPV em usuários de imunobiológicos, para o tratamento de doenças inflamatórias crônicas imunomediadas, com a de não usuários desta medicação. Materiais e métodos: Foram avaliados clinicamente e por reação em cadeia da polimerase (PCR), a positividade do HPV em 114 pacientes usuários de imunobiológicos (infliximabe, etanercepte, adalimumabe, secuquinumabe e ustequinumabe) para o tratamento de doenças inflamatórias crônicas imunomediadas (psoríase, artrite psoriásica, hidrosadenite supurativa, artrite reumatoide, espondilite anquilosante e doença de Chron) e 114 indivíduos não usuários desta terapia ou de outros imunossupressores, com dermatoses, exceto psoríase, e não portadores de condições predisponentes à infecção pelo HPV (diabetes mellitus, doenças hematológicas, infecção pelo HIV, hepatite B ou C, neoplasias e transplantes de órgãos). Resultados: A prevalência de HPV de baixo risco nos grupos usuários e não usuários de imunobiológicos foi de 16,3% e 10,3%, respectivamente (p= 0,524). Os tipos de baixo risco encontrados foram 6, 11, 40, 42 e 44. A prevalência de HPV de alto risco foi de 20,2% em usuários versus 18,4% em não usuários (p= 0,737), distribuídos segundo os tipos em: 16 (6,8%); 18 (11,4%); não 16/18 (81,8%). Após o pareamento por sexo e idade, a prevalência de HPV de alto risco foi de 21,0% e 12,9% para usuários e não usuários de imunobiológico, respectivamente (p= 0,231). Separando por classe de imunobiológicos, a prevalência de HPV de alto risco entre usuários de anti-TNF-α foi de 20,0% e de anti-IL 21,6%, sem associação significativa (p= 0,482). Assim, não foi constatada associação de ambos os grupos com as prevalências de HPV de baixo risco ou de alto risco. Conclusão: A prevalência da infecção anogenital pelo HPV, em pacientes com doenças inflamatórias crônicas imunomediadas, tratados com imunobiológicos, é semelhante à de pacientes não usuários destes medicamentos.Submitted by Jakeline Ortega (jakortega@unoeste.br) on 2021-04-12T18:17:26Z No. of bitstreams: 2 Eduardo Vinicius Mendes Roncada.pdf: 2197948 bytes, checksum: b0ae1f2292c171df4e7e3ff47ad1910b (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Made available in DSpace on 2021-04-12T18:17:26Z (GMT). No. of bitstreams: 2 Eduardo Vinicius Mendes Roncada.pdf: 2197948 bytes, checksum: b0ae1f2292c171df4e7e3ff47ad1910b (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2021-02-23application/pdfhttp://bdtd.unoeste.br:8080/jspui/retrieve/4174/Eduardo%20Vinicius%20Mendes%20Roncada.pdf.jpgporUniversidade do Oeste PaulistaMestrado em Ciências da SaúdeUNOESTEBrasilMestrado em Ciências da Saúdehttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessAnticorpos MonoclonaisCondiloma AcuminadoInflamaçãoDoenças Virais Sexualmente TransmissíveisImunossupressoresMonoclonal antibodiesCondyloma AcuminateInflammationSexually Transmitted Viral DiseasesImmunosuppressantsCIENCIAS DA SAUDE::MEDICINAPrevalência da infecção anogenital pelo papilomavírus humano (HPV) em usuários de terapia imunobiológicaPrevalence of anogenital infection by human papillomavirus (HPV) in users of immunobiological therapyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesis45484740625200741685005006004548474062520074168-969369452308786627reponame:Biblioteca Digital de Teses e Dissertações da UNOESTEinstname:Universidade do Oeste Paulista (UNOESTE)instacron:UNOESTETHUMBNAILEduardo Vinicius Mendes Roncada.pdf.jpgEduardo Vinicius Mendes Roncada.pdf.jpgimage/jpeg3348http://bdtd.unoeste.br:8080/tede/bitstream/jspui/1329/7/Eduardo+Vinicius+Mendes+Roncada.pdf.jpgdc703d7ab590d501851a3d21e1c8e6cfMD57TEXTEduardo Vinicius Mendes Roncada.pdf.txtEduardo Vinicius Mendes Roncada.pdf.txttext/plain118194http://bdtd.unoeste.br:8080/tede/bitstream/jspui/1329/6/Eduardo+Vinicius+Mendes+Roncada.pdf.txt711aec97b5d6b671af76bc4229aebf9cMD56ORIGINALEduardo Vinicius Mendes Roncada.pdfEduardo Vinicius Mendes Roncada.pdfapplication/pdf2197948http://bdtd.unoeste.br:8080/tede/bitstream/jspui/1329/5/Eduardo+Vinicius+Mendes+Roncada.pdfb0ae1f2292c171df4e7e3ff47ad1910bMD55CC-LICENSElicense_urllicense_urltext/plain; charset=utf-849http://bdtd.unoeste.br:8080/tede/bitstream/jspui/1329/2/license_url4afdbb8c545fd630ea7db775da747b2fMD52license_textlicense_texttext/html; charset=utf-80http://bdtd.unoeste.br:8080/tede/bitstream/jspui/1329/3/license_textd41d8cd98f00b204e9800998ecf8427eMD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-80http://bdtd.unoeste.br:8080/tede/bitstream/jspui/1329/4/license_rdfd41d8cd98f00b204e9800998ecf8427eMD54LICENSElicense.txtlicense.txttext/plain; charset=utf-82067http://bdtd.unoeste.br:8080/tede/bitstream/jspui/1329/1/license.txt47745281809acb27fb322a97f2d9cb88MD51jspui/13292021-04-13 01:01:43.711oai:bdtd.unoeste.br: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 Digital de Teses e Dissertaçõeshttp://bdtd.unoeste.br:8080/jspui/PUBhttp://bdtd.unoeste.br:8080/oai/requestbdtd@unoeste.bropendoar:2021-04-13T04:01:43Biblioteca Digital de Teses e Dissertações da UNOESTE - Universidade do Oeste Paulista (UNOESTE)false |
dc.title.por.fl_str_mv |
Prevalência da infecção anogenital pelo papilomavírus humano (HPV) em usuários de terapia imunobiológica |
dc.title.alternative.eng.fl_str_mv |
Prevalence of anogenital infection by human papillomavirus (HPV) in users of immunobiological therapy |
title |
Prevalência da infecção anogenital pelo papilomavírus humano (HPV) em usuários de terapia imunobiológica |
spellingShingle |
Prevalência da infecção anogenital pelo papilomavírus humano (HPV) em usuários de terapia imunobiológica RONCADA, Eduardo Vinicius Mendes Anticorpos Monoclonais Condiloma Acuminado Inflamação Doenças Virais Sexualmente Transmissíveis Imunossupressores Monoclonal antibodies Condyloma Acuminate Inflammation Sexually Transmitted Viral Diseases Immunosuppressants CIENCIAS DA SAUDE::MEDICINA |
title_short |
Prevalência da infecção anogenital pelo papilomavírus humano (HPV) em usuários de terapia imunobiológica |
title_full |
Prevalência da infecção anogenital pelo papilomavírus humano (HPV) em usuários de terapia imunobiológica |
title_fullStr |
Prevalência da infecção anogenital pelo papilomavírus humano (HPV) em usuários de terapia imunobiológica |
title_full_unstemmed |
Prevalência da infecção anogenital pelo papilomavírus humano (HPV) em usuários de terapia imunobiológica |
title_sort |
Prevalência da infecção anogenital pelo papilomavírus humano (HPV) em usuários de terapia imunobiológica |
author |
RONCADA, Eduardo Vinicius Mendes |
author_facet |
RONCADA, Eduardo Vinicius Mendes |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Abreu, Marilda Aparecida Milanez Morgado de |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/7386113426973769 |
dc.contributor.referee1.fl_str_mv |
Nai, Gisele Alborghetti |
dc.contributor.referee1ID.fl_str_mv |
https://orcid.org/0000-0003-1674-7371 |
dc.contributor.referee1Lattes.fl_str_mv |
http://lattes.cnpq.br/6057606215850166 |
dc.contributor.referee2.fl_str_mv |
Duarte, Artur Antonio |
dc.contributor.referee2Lattes.fl_str_mv |
http://lattes.cnpq.br/6738651856959288 |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/8687483769115762 |
dc.contributor.author.fl_str_mv |
RONCADA, Eduardo Vinicius Mendes |
contributor_str_mv |
Abreu, Marilda Aparecida Milanez Morgado de Nai, Gisele Alborghetti Duarte, Artur Antonio |
dc.subject.por.fl_str_mv |
Anticorpos Monoclonais Condiloma Acuminado Inflamação Doenças Virais Sexualmente Transmissíveis Imunossupressores |
topic |
Anticorpos Monoclonais Condiloma Acuminado Inflamação Doenças Virais Sexualmente Transmissíveis Imunossupressores Monoclonal antibodies Condyloma Acuminate Inflammation Sexually Transmitted Viral Diseases Immunosuppressants CIENCIAS DA SAUDE::MEDICINA |
dc.subject.eng.fl_str_mv |
Monoclonal antibodies Condyloma Acuminate Inflammation Sexually Transmitted Viral Diseases Immunosuppressants |
dc.subject.cnpq.fl_str_mv |
CIENCIAS DA SAUDE::MEDICINA |
description |
Introduction: Patients using immunobiological drugs are at increased risk of presenting or reactivating latent or occult infections and unnoticed neoplasms. Screening prior to the use of these drugs includes warding off infections, including tuberculosis, viral hepatitis B and C, syphilis, human immunodeficiency virus (HIV), and opportunistic pathogens in immunosuppressed patients. However, human papillomavirus (HPV), a highly prevalent agent in our country and precursor of benign or even carcinogenic warts, is not routinely screened. Information on HPV infection in immunobiological users is scarce or conflicting, and there are no studies evaluating the prevalence of HPV in the anogenital region among users of different classes of these medications for the treatment of different immunomediated chronic inflammatory diseases, when compared to that of non-users of this medication. Objective: To compare the prevalence of anogenital HPV infection in immunobiological users for the treatment of immunomediated chronic inflammatory diseases with that of non-users of this medication. Materials and methods: HPV positivity in 114 immunobiological users (infliximab, etanercept, adalimumab, secuquinumab and ustequinumab) were evaluated clinically and by polymerase chain reaction (PCR) for the treatment of immunomediated chronic inflammatory diseases (psoriasis, psoriatic arthritis, suputive hydrosadenitis, rheumatoid arthritis, ankylosing spondylitis and Chron's disease) and 114 individuals not using this therapy or other immunosuppressants, with dermatoses, except psoriasis, and not carriers of conditions predisposing to HPV infection (diabetes mellitus, hematological diseases, HIV infection, hepatitis B or C, neoplasms and organ transplants). Results: The prevalence of low-risk HPV in the immunobiological users and non-users groups was 16.3% and 10.3%, respectively (p= 0.524). The low-risk types found were 6, 11, 40, 42 and 44. The prevalence of high-risk HPV was 20.2% in users versus 18.4% in non-users (p= 0.737), distributed according to the following types: 16 (6.8%); 18 (11.4%); not 16/18 (81.8%). After pairing by gender and age, the prevalence of high-risk HPV was 21.0% and 12.9% for immunobiological users and non-users, respectively (p= 0.231). Separating by class of immunobiologicals, the prevalence of high-risk HPV among users of anti-TNF-α was 20.0% and anti-IL 21.6%, with no significant association (p= 0.482). Thus, there was no association between both groups and the prevalence of low-risk or high-risk HPV. Conclusion: The prevalence of anogenital HPV infection in patients with chronic immune-mediated inflammatory diseases treated with immunobiologicals is similar to that of patients not using these drugs. |
publishDate |
2021 |
dc.date.accessioned.fl_str_mv |
2021-04-12T18:17:26Z |
dc.date.issued.fl_str_mv |
2021-02-23 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
RONCADA , Eduardo Vinicius Mendes. Prevalência da infecção anogenital pelo papilomavírus humano (HPV) em usuários de terapia imunobiológica. 2021. Dissertação (Mestrado em Ciências da Saúde) - Universidade do Oeste Paulista, Presidente Prudente, SP, 2021 . |
dc.identifier.uri.fl_str_mv |
http://bdtd.unoeste.br:8080/jspui/handle/jspui/1329 |
identifier_str_mv |
RONCADA , Eduardo Vinicius Mendes. Prevalência da infecção anogenital pelo papilomavírus humano (HPV) em usuários de terapia imunobiológica. 2021. Dissertação (Mestrado em Ciências da Saúde) - Universidade do Oeste Paulista, Presidente Prudente, SP, 2021 . |
url |
http://bdtd.unoeste.br:8080/jspui/handle/jspui/1329 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.program.fl_str_mv |
4548474062520074168 |
dc.relation.confidence.fl_str_mv |
500 500 600 |
dc.relation.department.fl_str_mv |
4548474062520074168 |
dc.relation.cnpq.fl_str_mv |
-969369452308786627 |
dc.rights.driver.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade do Oeste Paulista |
dc.publisher.program.fl_str_mv |
Mestrado em Ciências da Saúde |
dc.publisher.initials.fl_str_mv |
UNOESTE |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
Mestrado em Ciências da Saúde |
publisher.none.fl_str_mv |
Universidade do Oeste Paulista |
dc.source.none.fl_str_mv |
reponame:Biblioteca Digital de Teses e Dissertações da UNOESTE instname:Universidade do Oeste Paulista (UNOESTE) instacron:UNOESTE |
instname_str |
Universidade do Oeste Paulista (UNOESTE) |
instacron_str |
UNOESTE |
institution |
UNOESTE |
reponame_str |
Biblioteca Digital de Teses e Dissertações da UNOESTE |
collection |
Biblioteca Digital de Teses e Dissertações da UNOESTE |
bitstream.url.fl_str_mv |
http://bdtd.unoeste.br:8080/tede/bitstream/jspui/1329/7/Eduardo+Vinicius+Mendes+Roncada.pdf.jpg http://bdtd.unoeste.br:8080/tede/bitstream/jspui/1329/6/Eduardo+Vinicius+Mendes+Roncada.pdf.txt http://bdtd.unoeste.br:8080/tede/bitstream/jspui/1329/5/Eduardo+Vinicius+Mendes+Roncada.pdf http://bdtd.unoeste.br:8080/tede/bitstream/jspui/1329/2/license_url http://bdtd.unoeste.br:8080/tede/bitstream/jspui/1329/3/license_text http://bdtd.unoeste.br:8080/tede/bitstream/jspui/1329/4/license_rdf http://bdtd.unoeste.br:8080/tede/bitstream/jspui/1329/1/license.txt |
bitstream.checksum.fl_str_mv |
dc703d7ab590d501851a3d21e1c8e6cf 711aec97b5d6b671af76bc4229aebf9c b0ae1f2292c171df4e7e3ff47ad1910b 4afdbb8c545fd630ea7db775da747b2f d41d8cd98f00b204e9800998ecf8427e d41d8cd98f00b204e9800998ecf8427e 47745281809acb27fb322a97f2d9cb88 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Biblioteca Digital de Teses e Dissertações da UNOESTE - Universidade do Oeste Paulista (UNOESTE) |
repository.mail.fl_str_mv |
bdtd@unoeste.br |
_version_ |
1785359475447693312 |